Dr. Samuel Lora is the Clinical Pharmacology Reviewer at GLPOneMedical. He is the lead reviewer for compounded vs branded distinctions, drug interactions, the 503A/503B pharmacy framework, and the salt-vs-base active-ingredient question that drives so much of the regulatory uncertainty around compounded GLP-1.
Background
Dr. Lora is a board-certified physician with subspecialty interest in clinical pharmacology and telehealth medicine. His professional interest spans pharmaceutical manufacturing standards, compounding pharmacy oversight, and the operational integrity of telehealth prescribing.
Role at GLPOneMedical
As Clinical Pharmacology Reviewer, Dr. Lora:
- Reviews all pages related to compounded vs branded distinctions, pharmacy framework, and the salt vs base API question.
- Reviews drug-interaction content and the comprehensive interactions reference.
- Reviews the 503A/503B compounding-framework guide and regulatory analyses.
- Reviews provider-pharmacy-disclosure claims as part of the standard review workflow.
Areas of expertise
- Compounding pharmacy framework — 503A vs 503B distinction, USP <797>, USP <85>, USP <71>, cGMP, state pharmacy board authority.
- Salt vs base active ingredients — why FDA flagged semaglutide sodium and acetate as unapproved API and what it means for compounded supply.
- Drug interactions — GLP-1 receptor agonists with insulin, sulfonylureas, oral contraceptives (tirzepatide-specific), pre-procedure anesthesia considerations.
- Telehealth prescribing — operational and clinical-integrity considerations.
Recent reviews signed off
- Comprehensive drug interactions
- 503A vs 503B framework
- April 2026 FDA action analysis
- Fact-checking policy
Conflicts of interest
None disclosed beyond the standard editorial-retainer arrangement with Ranika Partners LLC. No advisory or compensation relationships with any provider reviewed on this site. No employment or consulting relationship with any compounding pharmacy. Full conflicts disclosure: /conflicts-of-interest.html.
Contact
glponemedical@gmail.com (subject line: "Medical advisory board / Dr. Lora").